<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation-en.html</loc>
    <news:news>
      <news:publication>
        <news:name>Drugnews｜藥時事</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>Winning First Is Not Winning: Roche&apos;s Divarasib Pushes KRAS Into a Generational Elimination Race</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation.html</loc>
    <news:news>
      <news:publication>
        <news:name>Drugnews｜藥時事</news:name>
        <news:language>zh-tw</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>先贏不是贏：Roche divarasib 把 KRAS 賽道推進世代淘汰戰</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns.html</loc>
    <news:news>
      <news:publication>
        <news:name>Drugnews｜藥時事</news:name>
        <news:language>zh-tw</news:language>
      </news:publication>
      <news:publication_date>2026-07-11T01:49:15.886Z</news:publication_date>
      <news:title>社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns-en.html</loc>
    <news:news>
      <news:publication>
        <news:name>Drugnews｜藥時事</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-11T01:49:00.000Z</news:publication_date>
      <news:title>Fasedienol&apos;s Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job.</news:title>
    </news:news>
  </url>
</urlset>
